Literature DB >> 6362383

Improved exercise tolerance after propranolol, diltiazem or nifedipine in angina pectoris: comparison at 1, 3 and 8 hours and correlation with plasma drug concentration.

B R Chaitman, P Wagniart, A Pasternac, G Brevers, J M Scholl, J Lam, M Methe, R J Ferguson, M G Bourassa.   

Abstract

Exercise tolerance 1, 3 and 8 hours after 80 mg of propranolol, 120 mg of diltiazem and 20 mg of nifedipine, and after 20 minutes of 0.6 mg of sublingual nitroglycerin were compared with placebo in 15 men who had chronic stable angina pectoris. Three hours after drug ingestion, the exercise time was prolonged by 72 +/- 26, 162 +/- 27 and 161 +/- 30 seconds (p less than 0.05) for propranolol, diltiazem and nifedipine, respectively, and by 123 +/- 35 seconds (p less than 0.001) 20 minutes after sublingual nitroglycerin compared with placebo. The onset of ST-segment depression greater than or equal to 0.1 mV was delayed by 120 +/- 34, 203 +/- 29 and 189 +/- 35 seconds (p less than 0.05) and by 79 +/- 23 seconds (p less than 0.05), respectively. After propranolol, the peak rate-pressure product decreased compared with placebo (15.1 +/- 1.1 U [10(-3)] vs 20.0 +/- 1.5 U, p less than 0.01). In contrast, the peak rate-pressure product was greater after diltiazem and nifedipine than after placebo (22.2 +/- 1.3 U [p less than 0.05] and 23.8 +/- 1.4 U [p less than 0.01]). The maximal increase in exercise tolerance was most marked for each drug at 3 hours, but was also significant at 1 hour for nifedipine and at 8 hours for diltiazem. At 3 hours, an increase in exercise time of more than 2 minutes was observed in 4 of 6 patients who had plasma propranolol concentrations greater than 40 ng/ml, 8 of 9 who had a plasma diltiazem concentration greater than 150 ng/ml, and in 7 of 7 who had a plasma nifedipine concentration greater than 90 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362383     DOI: 10.1016/0002-9149(84)90674-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

Review 1.  The combination of slow-release nifedipine and atenolol for stable angina.

Authors:  D G Waller; V F Challenor
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 3.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 4.  Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; C F George
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

5.  Effects of diltiazem and isosorbide-5-mononitrate, alone and in combination, on patients with stable angina pectoris.

Authors:  H Emanuelsson; H Ake; M Kristi; R Arina
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris.

Authors:  M Picca; F Azzollini; A Cereda; G Pelosi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Effect of diltiazem and propranolol on myocardial ischaemia during unrestricted daily life in patients with effort-induced chronic stable angina pectoris.

Authors:  N S Khurmi; M J O'Hara; M J Bowles; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

9.  Slow release nifedipine plus atenolol in chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

10.  Evaluation of the antianginal effect of nifedipine: influence of formulation dependent pharmacokinetics.

Authors:  B W Karlson; H Emanuelsson; J Herlitz; J E Nilsson; G Olsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.